dc.creator | Komiotis, D. | en |
dc.creator | Manta, S. | en |
dc.creator | Tsoukala, E. | en |
dc.creator | Tzioumaki, N. | en |
dc.date.accessioned | 2015-11-23T10:35:24Z | |
dc.date.available | 2015-11-23T10:35:24Z | |
dc.date.issued | 2008 | |
dc.identifier | 10.2174/187152108785908848 | |
dc.identifier.issn | 18715214 | |
dc.identifier.uri | http://hdl.handle.net/11615/29583 | |
dc.description.abstract | In the search for effective, selective and nontoxic antiviral agents, a variety of nucleoside analogues have been synthesized, with different functionalities in the carbohydrate moiety. Unsaturated nucleoside analogues are recognized as an important class of biologically active compounds and appear to be prominent drugs in the management of several viral infections, including HSV, HIV, HBV, HCV and HCMV infections. Currently, unsaturated nucleoside mimetics, such as stavudine, abacavir and entecavir have been approved for the treatment of viral infections, while elvucitabine and β-L-2′-F-d4C are in clinical trials. The purpose of this review is to give an update of the recent developments on unsaturated nucleoside and nucleoside analogues, in both cyclic and acyclic forms, which possess promising therapeutic potential, mainly antiviral. It covers analogues with ring sizes from three to six and provides useful data, in the aim to enhance chemical reactivity or to study the fixation of the sugar conformation. © 2008 Bentham Science Publishers Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-60149097227&partnerID=40&md5=b09f4128910e008508832ee45bb6f009 | |
dc.subject | Acyclic | en |
dc.subject | Antiviral | en |
dc.subject | Carbocyclic | en |
dc.subject | Exomethylene | en |
dc.subject | Unsaturated nucleosides | en |
dc.subject | 1',2' unsaturated nucleoside derivative | en |
dc.subject | 2' azido 2',3' unsaturated nucleoside derivative | en |
dc.subject | 2' c cyano 2',3' unsaturated nucleoside derivative | en |
dc.subject | 2' fluoro 2',3' unsaturated nucleoside derivative | en |
dc.subject | 2',3' unsaturated nucleoside derivative | en |
dc.subject | 3' azido 2',3' unsaturated nucleoside derivative | en |
dc.subject | 3' c cyano 2',3' unsaturated nucleoside derivative | en |
dc.subject | 3' c trifluoromethyl 2',3' dextro unsaturated nucleoside derivative | en |
dc.subject | 3' fluoro 2',3' unsaturated nucleoside derivative | en |
dc.subject | 3',4' unsaturated nucleoside derivative | en |
dc.subject | abacavir | en |
dc.subject | aciclovir | en |
dc.subject | acyclic unsaturated nucleoside derivative | en |
dc.subject | antivirus agent | en |
dc.subject | carbocyclic unsaturated nucleoside derivative | en |
dc.subject | cyclobutyl unsaturated nucleoside derivative | en |
dc.subject | cyclopentyl unsaturated nucleoside derivative | en |
dc.subject | cyclopropyl unsaturated nucleoside derivative | en |
dc.subject | elvucitabine | en |
dc.subject | entecavir | en |
dc.subject | exocyclic methylene nucleoside derivative | en |
dc.subject | nucleoside analog | en |
dc.subject | stavudine | en |
dc.subject | synadenol | en |
dc.subject | synguanol | en |
dc.subject | tezacitabine | en |
dc.subject | thio unsaturated nucleoside derivative | en |
dc.subject | unclassified drug | en |
dc.subject | unindexed drug | en |
dc.subject | unsaturated nucleoside derivative | en |
dc.subject | zidovudine | en |
dc.subject | acquired immune deficiency syndrome | en |
dc.subject | antiviral activity | en |
dc.subject | chemical reaction kinetics | en |
dc.subject | combination chemotherapy | en |
dc.subject | cytotoxicity | en |
dc.subject | drug potency | en |
dc.subject | drug screening | en |
dc.subject | drug synthesis | en |
dc.subject | human | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | IC 50 | en |
dc.subject | monotherapy | en |
dc.subject | nonhuman | en |
dc.subject | review | en |
dc.subject | structure activity relation | en |
dc.subject | virus replication | en |
dc.title | Antiviral unsaturates nucleosides | en |
dc.type | journalArticle | en |